利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.039 秒)

    COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE
    1.
    发明申请
    COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE 有权
    使用重组MHC分子进行治疗的组合物和方法

    公开(公告)号：US20150343055A1

    公开(公告)日：2015-12-03

    申请号：US14732145

    申请日：2015-06-05

    申请人： Oregon Health & Science University ,  The United States Government as represented by the Department of Veterans Affairs

    发明人： Halina Offner ,  Patricia D. Hurn ,  Arthur A. Vandenbark ,  Gregory G. Burrows

    IPC分类号： A61K39/385 ,  A61K45/06

    CPC分类号： A61K39/385 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/605 ,  A61K2039/627

    摘要： Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.

    摘要翻译： 双域MHC多肽可用于调节抗原特异性T细胞的活性，包括调节致病潜力和抗原特异性T细胞的作用。 本发明的示例性基于MHC II类的重组T细胞配体（RTL）包括共价连接的1和α1结构域，以及包含共价连接的α1和α2结构域的基于MHC I类的分子。 这些多肽还可以包括共价连接的抗原决定簇，毒性部分和/或可检测的标记。 所公开的多肽可用于靶向抗原特异性T细胞，并且除其他外，可用于检测和纯化抗原特异性T细胞，诱导或激活T细胞以调节T细胞活性，包括 通过T细胞因子和粘附分子表达的调节转换来治疗由抗原特异性T细胞介导的病症，包括治疗和/或预防与中风有关的中枢神经系统损伤。

    RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION
    2.
    发明申请
    RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION 有权
    用于治疗由物质摄入引起的认知和神经损伤的重建T细胞受体配体

    公开(公告)号：US20130273087A1

    公开(公告)日：2013-10-17

    申请号：US13924252

    申请日：2013-06-21

    申请人： The United States Government as represented by the Department of Veterans Affairs ,  Oregon Health & Science University

    发明人： Arthur A. Vandenbark ,  Gregory G. Burrows

    IPC分类号： C07K14/74

    CPC分类号： A61K39/0007 ,  A61B5/1124 ,  A61B5/165 ,  A61B5/168 ,  A61B5/4803 ,  A61K39/0013 ,  A61K45/06 ,  A61K2039/605 ,  C07K14/705 ,  C07K14/70539 ,  A61K2300/00

    摘要： Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.

    摘要翻译： 提供了用于治疗由物质成瘾引起的认知或神经精神障碍受试者和用于增加具有物质成瘾的受试者的认知功能的受试者的方法。 在一些实施方案中，所述方法包括向受试者施用治疗有效量的主要组织相容性复合物（MHC）分子，包括共价连接的第一，第二和第三结构域; 其中第一结构域是MHC II类β1结构域，第二结构域是MHC II类α1结构域; 或其中第一结构域为MHC I类α1结构域，第二结构域为MHC I类α2结构域; 并且其中所述第三结构域共价连接到所述第一结构域并且包含所述中枢神经系统或外周神经系统的抗原。

    COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE
    8.
    发明申请
    COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE 有权
    使用重组MHC分子进行治疗的组合物和方法

    公开(公告)号：US20140056936A1

    公开(公告)日：2014-02-27

    申请号：US13924275

    申请日：2013-06-21

    申请人： The United States Government as represented by the Department of Veterans Affairs ,  Oregon Health & Science University

    发明人： Halina Offner ,  Patricia D. Hurn ,  Arthur A. Vandenbark ,  Gregory G. Burrows

    IPC分类号： A61K39/00

    CPC分类号： A61K39/385 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/605 ,  A61K2039/627

    摘要： Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.

    摘要翻译： 双域MHC多肽可用于调节抗原特异性T细胞的活性，包括调节致病潜力和抗原特异性T细胞的作用。 本发明的示例性基于MHC II类的重组T细胞配体（RTL）包括共价连接的β1和α1结构域，以及包含共价连接的α1和α2结构域的基于MHC I类的分子。 这些多肽还可以包括共价连接的抗原决定簇，毒性部分和/或可检测的标记。 所公开的多肽可用于靶向抗原特异性T细胞，并且除其他外，可用于检测和纯化抗原特异性T细胞，诱导或激活T细胞以调节T细胞活性，包括 通过T细胞因子和粘附分子表达的调节转换来治疗由抗原特异性T细胞介导的病症，包括治疗和/或预防与中风有关的中枢神经系统损伤。

    Compositions and methods using recombinant MHC molecules for the treatment of stroke
    9.
    发明授权
    Compositions and methods using recombinant MHC molecules for the treatment of stroke 有权
    使用重组MHC分子治疗中风的组合物和方法

    公开(公告)号：US09492536B2

    公开(公告)日：2016-11-15

    申请号：US14732145

    申请日：2015-06-05

    申请人： Oregon Health & Science University ,  The United States of America as represented by the Department of Veterans Affairs

    发明人： Halina Offner ,  Patricia D. Hurn ,  Arthur A. Vandenbark ,  Gregory G. Burrows

    IPC分类号： A61K39/385 ,  A61K45/06 ,  A61K39/395 ,  A61K38/16 ,  A61K39/00

    CPC分类号： A61K39/385 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/605 ,  A61K2039/627

    摘要： Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke.

    摘要翻译： 双域MHC多肽可用于调节抗原特异性T细胞的活性，包括调节致病潜力和抗原特异性T细胞的作用。 本发明的示例性基于MHC II类的重组T细胞配体（RTL）包括共价连接的β1和α1结构域，以及包含共价连接的α1和α2结构域的基于MHC I类的分子。 这些多肽还可以包括共价连接的抗原决定簇，毒性部分和/或可检测的标记。 所公开的多肽可用于靶向抗原特异性T细胞，并且除其他外，可用于检测和纯化抗原特异性T细胞，诱导或激活T细胞以调节T细胞活性，包括 通过T细胞因子和粘附分子表达的调节转换来治疗由抗原特异性T细胞介导的病症，包括治疗和/或预防与中风有关的中枢神经系统损伤。